Xilonix: Additional Phase III data

XBiotech reported additional data from a double-blind, European Phase III trial in 309 patients with symptomatic, refractory, metastatic colorectal cancer evaluating IV Xilonix every 2 weeks plus

Read the full 272 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE